GlassScriptPhysician profile
Ethan Bernell Dalley
NPI 1780818112
$15,501.32
in general payments reported to CMS, 2019-2025
34 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what 87% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,134 · 2020: $984 · 2021: $1,894 · 2022: $1,247 · 2023: $3,241 · 2024: $2,927 · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,466 · Travel and Lodging: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,465.78 |
| Travel and Lodging | $1,775.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,752.91 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Accurian |
| Abbott Laboratories | $2,170.81 | 2019-2025 | Proclaim |
| Vertiflex, INC. | $1,569.25 | 2019 | |
| Medtronic USA, INC. | $1,497.79 | 2019-2020 | |
| Relievant Medsystems, INC. | $1,428.53 | 2023 | Intracept |
| Boston Scientific Corporation | $1,167.28 | 2020-2025 | Intracept Rf Probe, General - Therapies, Intracept |
| Abbvie INC. | $677.77 | 2021-2025 | Ubrelvy, Botox |
| Collegium Pharmaceutical, INC. | $544.65 | 2019-2025 | Xtampza |
| Si-Bone, INC. | $368.99 | 2019-2025 | |
| Pfizer INC. | $314.22 | 2019-2025 | |
| Mml US, INC. | $172.75 | 2024 | Reactiv8 |
| Teva Pharmaceuticals USA, INC. | $75.82 | 2019 | |
| Allergan, INC. | $74.67 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $73.64 | 2021 | |
| Stryker Corporation | $73.09 | 2025 | Optablate, Mild Device Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $69.17 | 2020-2023 | Monovisc |
| Saluda Medical Americas, INC. | $60.20 | 2025 | Evoke |
| Novartis Pharmaceuticals Corporation | $54.89 | 2020-2021 | |
| Spr Therapeutics, INC | $48.00 | 2022 | |
| Lilly USA, LLC | $32.71 | 2020-2021 | |
| Daiichi Sankyo INC. | $30.15 | 2019 | |
| Biodelivery Sciences International, INC. | $28.25 | 2020 | |
| Spinal Simplicity, LLC | $27.42 | 2023 | Ha Minuteman G3-R |
| Pacira Therapeutics, INC. | $26.11 | 2019-2020 | |
| Zyla Life Sciences, INC. | $22.20 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $20.47 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.09 | 2021 | |
| Nalu Medical, INC. | $15.75 | 2022 | |
| Horizon Therapeutics Plc | $14.97 | 2021 | |
| International Rehabilitative Sciences, INC | $14.74 | 2024 | Rs 4i Plus Sequential Stimulator |
| Biohaven Pharmaceutical Holding Company LTD. | $14.40 | 2022 | |
| Baudax Bio INC. | $13.88 | 2021 | |
| Lundbeck LLC | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Dalley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.